🇺🇸 FDA
Patent

US 9567402

Internalizing human monoclonal antibodies targeting prostate and other cancer cells

granted A61KA61K47/6811A61K47/6829

Quick answer

US patent 9567402 (Internalizing human monoclonal antibodies targeting prostate and other cancer cells) held by The Regents of the University of California expires Mon Feb 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Feb 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K47/6811, A61K47/6829, A61K47/6849, A61K47/6869